RxDoctor Payments Data

Jessica Calabro

Acute Care · Cumming, GANPI 1841880234

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 62.5% of it on its own, with 17 other manufacturers making up the rest. Among acute care clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,300in general payments, 2019–2025

Across 120 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$321
  • Takeda Pharmaceuticals U.S.A., Inc.$237
  • QOL Medical, LLC$223
  • Regeneron Healthcare Solutions, Inc.$71
  • Daiichi Sankyo Inc.$57
  • plus $328 from 12 others

What the payments were for

  • Food & beverage$3,14295%
  • Education$1585%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,300 in reported general payments places this provider in the 90th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide87$62,806
XifaxanRifaximin13$34,209
Omeprazole181$1,961
CholestyramineCholestyramine (With Sugar)19$1,637
Pantoprazole Sodium114$1,575
Esomeprazole Magnesium46$1,493
Sucralfate25$869
Lubiprostone13$863
Famotidine69$739
Amitriptyline Hcl22$307
Dicyclomine Hcl15$258
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine15$257
Ondansetron OdtOndansetron21$189
Metoclopramide Hcl13$91
Ondansetron Hcl22$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,063$62,80687 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$56$34,20913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 679 acute care providers in Georgia.

Other acute care in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →